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SUPPLEMENTARY FIGURE LEGENDS 
 
Figure S1: Role of VAPs, ORP1L and annexin A1 in MCSs between the ER and 
MVBs (related to Figure 1). 
(A) Hela cells mock transfected (Control) or transfected with wt-annexinA1 or 
annexinA1 mutants were stimulated with EGF and anti-EGFR 10nm gold and 
prepared for EM as described (Eden et al., 2010). MCSs with EGFR-MVBs were 
quantified in serial sections, with each MVB examined in every 70 nm section in 
which it was present (average of 6 sections/MVB). In parallel, cells were prepared for 
EM as described in supplemental experimental procedures and MCSs with EGFR-
MVBs quantified in 70nm random sections 
(B) Hela cells were transfected with non-targeting siRNA (siCON) or siRNA targeting 
VAPA and VAPB (siVAPs), ORP1L (siORP1L) or annexinA1 (siANXA1). Cell extracts 
were immunoblotted with antibodies for VAPA, VAPB, ORP1L, annexinA1, or tubulin, 
as indicated. 
(C) Hela cells transfected with cfp-VAPA were fixed and stained for GFP using pre-
embedding labelling with nanogold antibodies and gold enhancement prior to 
preparation for EM.  Cfp-VAPA specifically labels the ER including sites of contact 
with endocytic organelles (arrows). Bar, 200nm.  
(D,E) Hela cells transfected with non-targeting siRNA (siCON) or siRNA targeting 
VAPA and VAPB (siVAPs) or ORP1L (siORP1L) were stimulated with EGF for the 
indicated times, cell lysates blotted with antibodies to phosphotyrosine(pY)1068 or 
total EGFR (D), and quantified (E). Data are mean ± SD of 3 experiments.  
(F) Hela cells stably overexpressing wtPTP1B or nontransfected controls were 
transfected with non-targeting siRNA (siCON) or siRNA targeting annexinA1 
(siANXA1) and stimulated with EGF for the indicated times and treated as in (D).  
(G) Hela cells transfected with annexinA1-gfp (ANXA1-gfp) were stained for gfp by 
pre-embedding labelling. Arrows indicate the position of MCSs between MVBs and 
the ER, Bar, 200nm.  
 
 
Figure S2: Correlation between requirements for ER MCSs with EGFR-MVBs 
and intralumenal vesicle formation (related to Figure 2).  
(A) RNA was isolated from Hela cells transfected with a non-targeting siRNA (siCON) 
or siRNA targeting S100A11 (siS100A11) for quantitative RT-PCR analysis of 
S100A11 expression.  Values were normalised to GAPDH mRNA and data shown as 
mean ± SD of 3 experiments. 
(B,C) Hela cells transfected with non-targeting siRNA (siCON) or siRNA targeting 
S100A11 (siS100A11) were stimulated with EGF for the indicated times, cell lysates 
blotted with antibodies to phosphotyrosine(pY)1068 or total EGFR (B), and quantified 
(C). Data are mean ± SD of 3 experiments.  
(D) AnnexinA1 (wtANXA1) is phosphorylated at tyrosine residue (Y) 21 in the N 
terminus by EGFR kinase activity. Mutagenesis of Y21 results in annexinA1 that 
cannot be phosphorylated by EGFR kinase activity (phosphorylation mutant Y21F-
ANXA1) or that mimics constitutive phosphorylation (phosphomimetic Y21E-ANXA1). 
(E) Hela cells transfected with annexinA1-myc were stimulated with EGF for the 
indicated times and annexinA1-myc immunoprecipitates were western blotted with 
anti-EGFR antibody.  
 
Figure S3: In the absence of LDL EGF-stimulated ILV formation depends on 
annexinA1-dependent transport of ER-derived cholesterol to EGFR-MVBs 
(related to Figure 3).    
(A) Statins block the production of proteins required for prenylation as well as 
cholesterol.  Squalene is a cholesterol precursor downstream of statin activity.  
(B) Hela cells cultured overnight in delipidated serum in the absence (LPDS) or 
presence (plus STATIN) or statin and squalene (plus SQUALENE) were stimulated 
with EGF in the presence of anti-EGFR 10nm gold conjugate and prepared for EM.  
The number of ILVs per EGFR-MVB was quantified.   
(C) Hela cells transfected with phosphomimetic Y21E-ANXA1gfp plasmid were 
cultured overnight in LPDS and stimulated with fluorescent EGF for 30 min.  Co-
localisation maps show that more intracellular filipin staining (blue) co-localises 
(white) with EGF (red) in Y21E-ANXA1gfp-expressing than in non-expressing 
(Control) cells. Scale bar, 5µm. 
(D,E) Hela cells were transfected with non-targeting siRNA (siCON) or siRNA 
targeting NPC1 (siNPC1) and cultured overnight in medium containing 10% LPDS or 
10% FCS. Cryosections were labelled for free cholesterol with PFO (10nm) and PFO 
label in MVBs quantified (D). Data shown are mean ± SEM. Representative images 
shown in E. The amount of PFO-labelling reflects the predicted endosomal 
cholesterol content (lowest in the absence of endocytosed cholesterol and highest 
when cholesterol egress from endosomes is blocked by NPC1 depletion). Scale bar, 
200nm. 
(F) Hela cells mock transfected (siCon) or transfected with siRNA targeting 
annexinA1 (siANXA1) or with Y21E-annexinA1-gfp plasmid (Y21E-ANXA1gfp) were 
cultured overnight in 10% LPDS prior to stimulation with EGF and 5nm-anti-EGFR-
gold conjugate. Cryosections were labelled for free cholesterol with PFO (10nm) and 
for Y21E-annexinA1gfp (15nm).  PFO label in EGFR-MVBs (white arrows) is absent 
in cells depleted of annexinA1, but increased in cells expressing Y21E-
annexinA1gfp. Scale bar, 200nm 
 
 
Figure S4: In the absence of LDL EGF-stimulated ILV formation depends on 
interaction between VAPs and ORP1L (related to Figure 4). 
(A,B) Hela cells transfected with a non-targeting siRNA (siCON) or siRNA targeting 
VAPA and VAPB (siVAP) were cultured overnight in LPDS and stimulated with EGF 
and anti-EGFR gold (A). The number of ILVs per EGFR-MVB was quantified and 
data shown is mean ± SD of 3 experiments (B).   
(C) Hela cells were transfected with wtORP1L-gfp or a FFAT motif mutant ORP1L-
gfp construct (mutORP1Lgfp) prior to overnight incubation in LPDS. Anti-gfp 
immunoprecipitates were blotted with anti-VAPA or anti-ORP1L antibodies. 
(D) Hela cells transfected with non-targeting siRNA (siCON) or siRNA targeting 
ORP1L (siORP1L) were fixed and stained for ORP1L by immunofluorescence. 
(E-G). Hela cells depleted of ORP1L were transfected with wtORP1L-gfp or a FFAT 
motif mutant ORP1L-gfp construct (mutORP1Lgfp). Cell lysates were Western 
blotted with anti-ORP1L antibody (E) or cells were fixed and imaged by confocal 
microscopy (F). Transfection efficiencies were calculated as % cells expressing gfp 
and expressed as mean ± SD of 3 experiments (G).  
 (H,I) Hela cells treated with non-targeting siRNA (siCON) or siRNA targeting ORP1L 
(siORP1L) and cultured in LPDS were transfected with phosphomimetic Y21E-
annexinA1-gfp (Y21E-ANXA1gfp), stimulated with EGF for 30 min and filipin-stained 
for free cholesterol. *:GFP-expressing cells; scale bar, 5µm (H).  Intracellular filipin 
staining was measured in non-expressing cells (nonEXP) and cells expressing the 
phosphomimetic annexinA1 (Y21Egfp) and normalised to non-expressing cells (I). 
(J) Hela cells transfected with ORP1L-gfp were fixed and stained for GFP using pre-
embedding labelling with nanogold antibodies and gold enhancement prior to 
preparation for EM.  ORP1L overexpression induces the formation of extended 
MCSs between MVBs and the ER that stain for ORP1L. Scale bar, 200nm.  
 
 
SUPPLEMENTARY EXPERIMENTAL PROCEDURES: 
 
Antibodies, plasmids and siRNAs: Mouse anti-VAPA and VAPB antibodies were 
from R&D Systems, rabbit anti-ORP1L was a kind gift from Vesa Olkkonen 
(University of Helsinki), rabbit anti-GFP was from Invitrogen, mouse anti-annexinA1 
was from Dianova, rabbit anti-pY1068-EGFR was from Cell Signaling and sheep 
anti-EGFR was from Fitzgerald, rabbit anti-S100A11 was from Proteintech Europe 
and rabbit anti-GST was from Abcam. Antibody to the extracellular domain of EGFR 
used for gold conjugation was isolated from the Mab 108 hybridoma (ATCC).  
Plasmids: cfpVAPA (Wyles et al., 2002) was a kind gift from Neale Ridgway 
(Dalhousie University), AnnexinA1gfp and Y21 mutants were as previously 
described(White et al., 2006), PTP1Bmyc and D181A mutant were as previously 
described (Eden et al., 2010) and wtORP1Lgfp and FFAT motif mutant were a kind 
gift from Jacques Neefjes (Netherlands Cancer Institute). 
siRNAs: The non-targeting control siRNA was Allstars negative control siRNA 
(Qiagen 1027281). siRNA duplexes targeting VAPA (M-021382-01), VAPB (M-
017795-00), ORP1L (D-008350-19) and S100A11 (D-012138-03) were synthesized 
by Dharmacon. The siRNA targeting annexinA1 was as previously described(White 
et al., 2006), synthesized by Qiagen. 
Electron microscopy: For conventional EM, cells on thermanox coverslips (NUNC) 
in DMEM/10%FBS or DMEM/10%LPDS with or without 10µM Mevastatin (Sigma), or 
1mM Squalene (Sigma) or 25µg/ml LDL were serum starved for 1h prior to 
stimulation with either 100ng/ml EGF (Sigma) or EGF conjugated to HRP with or 
without 10nm anti-EGFR gold conjugate in DMEM/0.2% BSA.  After fixation in 2% 
paraformaldehyde (PFA)/2% glutaraldehyde for 30 min, cells were post-fixed in 1% 
osmium tetroxide, 1.5% potassium ferricyanide, incubated in 1% uranyl acetate, 
dehydrated and embedded in TAAB-812 resin. For calcium chelation, cells were 
incubated in 100mM BAPTA-AM during serum-starvation and EGF-stimulation. For 
pre-embedding labelling, EGF-HRP was prepared by mixing 5 µg of streptavidin-HRP 
(Invitrogen) and 0.3 µg of biotinylated EGF (Invitrogen) in 300 µl for 1h. Cells were 
stimulated with EGF-HRP, fixed in 4% PFA, permeabilised in 40µg/ml digitonin 
(Calbiochem) and incubated with primary and nanogold-secondary (Nanoprobes) 
antibodies prior to fixation for EM in 2% PFA/2% glutaraldehyde. Cells stimulated 
with EGF-HRP were then incubated with 1.5mg/ml DAB (TAAB) in TRIS buffer 
supplemented with 0.02% H2O2 for 30 min, prior to gold enhancement (Nanoprobes), 
according to manufacturer’s instructions. Post-fixation and embedding were as for 
conventional EM. For cryo-immunoEM cells were serum starved for 1h prior to 
stimulation with EGF and 5nm anti-EGFR gold conjugate. Fixation, processing and 
labelling were performed essentially as described (Eden et al., 2010). Ultrathin cryo-
sections were labelled with mouse anti-myc, rabbit anti-GFP, or 20µg/ml PFO-GST 
(Kwiatkowska et al., 2014) followed by rabbit anti-GST and proteinA-gold.  
EM Quantitation: As MCSs with a given MVB may not be in the plane of a random 
section, MCSs were initially quantified in serial sections. However, as this is 
extremely time consuming and not practical for the scale of the experiments 
described in this study, staining and embedding was optimized (as above), which 
allowed MCSs in random sections to be counted, essentially reproducing the data 
from serial sections (Figure S1A). Random sections were then used throughout the 
study. For ILV and MCS quantitation, means, standard deviations (SD) and paired, 2-
tailed students T-tests were calculated in excel, with values >0.05 represented as not 
significant (ns), * <0.05, ** <0.01 and *** <0.001.   
For quantitation of PFO labeling, cryo-immunoEM cholesterol labeling with PFO was 
first validated by comparing the number of PFO-gold particles per MVB in control 
cells cultured in LPDS (low cholesterol) or in medium containing 10% FCS (steady 
state) of in cells depleted of NPC1 and cultured in medium containing 10% FCS (high 
cholesterol). Culturing cells in FCS compared with LPDS resulted in an 
approximately 4-fold increase in PFO label at MVBs, while an additional 3-fold 
increase was observed in cells depleted of NPC1 (Figure S3D,E), confirming the 
suitability of PFO as a quantitative cholesterol probe by cryo-immunoEM. 
Florescence Imaging: Cells on glass coverslips were fixed with 4% PFA in PBS for 
20 min, washed and mounted in Prolong Gold antifade reagent with or without (filipin-
stained cells) 4,6-diamidino-2-phenylindole (DAPI; Invitrogen). For EGF imaging, 
cells were serum starved for 1h and incubated with 200ng/ml Alexa 647-conjugated 
EGF (Invitrogen) in serum-free medium for 25-30 min prior to fixation. For cholesterol 
staining, cells were fixed in 4% PFA and incubated in 0.1mg/ml Filipin (Sigma). 
Images were acquired with a Leica DM-IRE2 microscope and TCS SP2 AOBS 
confocal system with a 63×/1.4 numerical aperture oil-immersion objective (Leica). 
Images were processed with Adobe Photoshop CS2 software (Adobe Systems). For 
quantitation, integrated densities relative to area were measured using ImageJ64 
and normalized to controls.  For colocalisation, manders coefficient was calculated 
using FIJI. Transfection efficiencies were calculated as the % of DAPI-stained cells 
positive for gfp. SDs were calculated in excel from data acquired over 3 experiments.  
 
Western blotting and immunoprecipitation: Cells were lysed in lysis buffer 
(40 mM HEPES, 80 mM NaCl, 10 mM EDTA, 10 mM EGTA, 1% Triton-X100, 
protease inhibitor cocktail (Calbiochem set I), phosphatase inhibitor cocktail 
(Calbiochem set II), lysates were fractioned by SDS–PAGE on 10% gels under 
reducing conditions and immunoblotted on nitrocellulose membranes. Following 
incubation with infrared-fluorophore-conjugated secondary antibodies, membranes 
were scanned in an Odyssey SA scanner (LI-COR Biosciences). Band densities 
were measured using FIJI and SDs were calculated in excel from data acquired over 
3 experiments. For immunoprecipitation, MYC- or GFP-tagged proteins were 
immunoprecipitated from cell lysates by incubation with Protein G PLUS-Agarose 
(Santa Cruz) and anti-MYC or -GFP antibody prior to immunoblotting. 
Quantitative RT-PCR: RNA was isolated using RNeasy (Qiagen) and treated with 
DNAse (Applied Biosystems), prior to quantitative RT-PCR using Power SYBR 
Green PCR master mix (Applied Biosystems), according to manufacturer’s 
instructions. Values were normalized to GAPDH in each sample. The primer 
sequences detailed below were synthesized by MWG: 
S100A11-F: 5ʹ′-CCTTGACCGCATGATGAAGA-3ʹ′ 
S100A11-R: 5ʹ′-CTAGGCCACCAATCAGATTAAGA-3ʹ′ 
GAPDH-F: 5ʹ′-GGAGTCAACGGATTTGGTCGTA-3ʹ′ 
GAPDH-R: 5- GGCAACAATATCCACTTTACCAGAGT-3ʹ′ 
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